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Objective. An audit was established in November 1999 by the Australian Government Department of Health and Ageing
to determine the mid- to long-term safety and efficacy of endoluminal graft repair (ELG) of abdominal aortic aneurysm
(AAA). The audit has been undertaken by the Australian Safety and Efficacy Register for New Interventional Procedures—
Surgical (ASERNIP-S). This study reviews contemporary Australian practice, based on audit data supplied to ASERNIP-S.
Design of study. This study is a prospective voluntary register (audit) of Australian data obtained from the private and
public sector. Data were collected for ELG repairs performed between 1 November 1999 and 16 May 2001. Follow-up is
continuing.
Results. Seventy-nine vascular surgeons have contributed data on 950 patients (816 male, 134 female, of median age 75.5
(range 36–94)). The mean aneurysm size was 57.5 mm (^10.2) and 44% of procedures were performed on aneurysms less
than 55 mm in diameter. Fifty four percent of patients were considered suitable for open repair.
Most ELG procedures were performed in an angiography or endovascular suite, under general anaesthetic using an open
technique via the femoral arteries. Perioperative mortality was 1.7%, mostly from cardiac causes. Prior to discharge 7.2% of
patients experienced an endoleak and 18.6% had systemic complications. The average length of stay was 7.4 days (median 5
days). Unsuccessful exclusion of the aneurysm occurred in 6.7% of cases.
Conclusions. Endovascular repair of AAAs is a well accepted procedure and is performed by the majority of vascular
surgeons in Australia. Australian surgeons are taking a rather aggressive approach to the management of aortic aneurysms,
particularly in the moderate to higher risk patient groups. Mortality rates are low, given the elderly population in question
and morbidity rates acceptable. ASERNIP-S is continuing to collect follow-up data for this patient cohort.
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Introduction
Endoluminal graft (ELG) repair of AAA was first
reported in 1991 by Parodi et al.1 During the next few
years important contributions to the application of this
technique were made by two Australian groups.2 In
1992, a group in Sydney led by J. May and G. White at
the Royal Prince Alfred Hospital started performing
ELG repair and have subsequently reported on a
number of stent-graft systems. In 1993, a group in
Perth led by M. Lawrence-Brown and D. Hartley
deployed their first stent-graft, which is now called the
Zenith graft (Cook Australia Pty, Brisbane, Australia),
and is the most commonly used graft in Australia.
During the last decade ELG repair has been widely
adopted within Australia and is currently performed
by the majority of vascular surgeons.
With the introduction of ELG repair came the
requirement to show that the grafts were safe and
durable.3 In 1999 the Australian Government Depart-
ment of Health and Ageing agreed to fund a national
audit, on the proviso that at least 95% of all privately
performed elective procedures were collected. Data
were also to be collected for procedures performed in
the public sector. The Australian Safety and Efficacy
Register of New Interventional Procedures—Surgical
(ASERNIP-S) established the audit, which has now
been in progress for over three years.
This review aims to give an overview of the current
role of ELG repair in contemporary Australian
vascular practice.
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Method
ASERNIP-S is a programme of the Royal Australasian
College of Surgeons (RACS), which has been funded to
audit ELG repair and assess the medium to long-term
results of the procedure. An audit reference group
comprising vascular surgeons with a high level of
expertise in the endoluminal procedure advises
ASERNIP-S on clinical aspects of the procedure.
Approval for the audit was obtained from the Ethics
Committee for the Royal Australasian College of
Surgeons.
Data were requested from surgeons for endo-
luminalproceduresperformedbetween the1November
1999 and 16May 2001. Additional data were requested
at discharge/early follow-up and ongoing follow-up
for each patient at 6 months, 12 months then annually
thereafter. Data are submitted either on paper forms or
using a secure online data entry system through the
ASERNIP-S web site. National aggregate results of the
audit are distributed to participating surgeons.
Results presented here were taken from the oper-
ative and discharge data sets, in order to develop an
overview of contemporary practice of ELG repair, with
particular reference to indications, technique and
initial results. The following clinico-pathological data
were collected: age, gender, presence/absence of co-
morbidities, aneurysm diameter and morphology,
preoperative imaging modalities, operative and
anaesthetic techniques, type of graft, peri-operative
mortality, intra-operative and post operative compli-
cations, early endoleak (based on intraoperative
angiography and postoperative CT scan), duration of
post operative hospital stay. The American Society of
Anaesthesiology (ASA) classification was used to
assess patient fitness for surgery. Peri-operative
mortality was defined as death within 30 days of the
procedure.
Surgeons were asked to decide prior to the
procedure, whether the patient was suitable for open
repair and possible randomisation to a trial of open
versus endovascular repair. Technical and clinical
success rates were calculated according to reporting
standards established by the Ad Hoc Committee for
standardized reporting practices in vascular surgery.4
Results
Up to 1 August 2003, a total of 950 ELG procedure
patients were enrolled in the audit of which 70% ðn ¼
667Þ were performed in the private sector and the
remainder in the public system. The 667 private
patients represented around 87% of all procedures
performed privately in Australia. Discharge/30 day
information was received for 930 (98%) patients. Fifty
four percent ðn ¼ 895Þ of patients were considered
suitable for potential randomisation to a trial of open
or endovascular surgery. The volume of ELG surgery
performed and ultimately submitted to ASERNIP-S
remained constant at around 50 cases per month.
Surgeon participation
Seventy-nine surgeons have contributed to the audit;
the number of procedures performed by each surgeon
is shown in Fig. 1. According to information provided
by the Health Insurance Commission, there were
approximately 18 surgeons who performed fewer
than five private procedures during the period of the
audit, but did not submit their data to the ASERNIP-S.
Some of these procedures may have been submitted
under an alternative surgeon’s name. Thus it appears
that over 90 vascular surgeons (i.e. over 65% of those
in active practice) perform the procedure on a regular
or occasional basis.
Anatomical features
Mean aneurysm diameter was 57 mm (^10.2). Where
maximum aneurysm diameter was reported ðn ¼ 921Þ;
a total of 44% ðn ¼ 407Þ of aneurysms measured less
than 55 mm in diameter, with 27% ðn ¼ 253Þ #50 mm
in diameter.
In terms of morphology, 69% (582/841) of aneur-
ysms did not extend beyond the aortic bifurcation and
a further 20% (167/841) had good iliac ‘landing zones’
proximal to the iliac bifurcation. Few cases had
difficult distal anatomy (approximately 4%). Twenty-
five percent (212/859) of patients had a ‘neck’ length
less than 20 mm and only 9% (81/859) were less than
15 mm. Eleven percent (105/950) of patients had
Fig. 1. Number of ELG procedures performed by Australian
vascular surgeons.
Australian Audit of AAA 37
Eur J Vasc Endovasc Surg Vol 28, July 2004
thrombus in the neck of the aneurysm and 20% had a
saccular aneurysm. Thirteen percent (124/950) of
patients were recorded with an aortic neck angle
$458, 1.5% (14/950) of patients were recorded with an
aneurysm angle $608.
Age and patient fitness
Most patients in the audit are male (86%, n ¼ 816). The
mean age (^SD) of patients enrolled in the audit is
75.0 ^ 6.9 years. Fifty-seven percent ðn ¼ 538Þ of
patients are 75 years or older, 34% ðn ¼ 345Þ fall within
the 65–74 years bracket and 7% ðn ¼ 67Þ are less than
65 years.
Overall, 33% of patients were categorised as ASA I
or II, 59% as ASA III and 6% as ASA IV. For patients
groups with an aneurysm diameter less than 55 and
#50 mm, 44% had an ASA of I or II, 54% had an ASA
of III and 2% had an ASA of IV (Table 1).
Imaging
Imaging done pre-operatively most commonly
included both spiral CT and angiography. The most
typical combination was spiral CT and angiography
(58%, n ¼ 539=932), but these two imaging techniques
were used in combination with other imaging tech-
niques in a further 20% of cases. Angiography was
used in 83% of cases. Spiral CT on its own accounted
for 11% ðn ¼ 99=932Þ of imaging.
Surgical details
Most procedures were performed in an angiography
or endovascular suite (67%, 609/910); the rest were
performed in an operating theatre. Around 74%
(680/922) of procedures were performed under gen-
eral anaesthesia, and epidural/spinal anaesthesia was
used in 26% (235/922) of cases. The most commonly
used main access vessel is the femoral artery (96%,
897/934), and access is usually open (92%, 855/930)
rather than percutaneous. The main type of graft used
in Australia during the period of audit was the Zenith
graft (Cook Australia) (83%, 785/946). The use of other
graft types was: Ancure (Guidant) 1.5% ðn ¼ 14Þ;
AneuRx(Medtronic) 6.5% ðn ¼ 62Þ; Excluder (W L
Gore) 4.3% ðn ¼ 41Þ; Talent (World Medical) 3.7% ðn ¼
35Þ; and Vanguard (Boston Scientific) 0.7% ðn ¼ 7Þ: The
aorto-bi-iliac-bifurcated design is the most common
configuration (92%, 865/938).
Technical and clinical success
(Assisted) primary technical success was 89.7% ðn ¼
853Þ and secondary technical success increased this to
92.8% ðn ¼ 883Þ: It was not possible to distinguish
between planned and unplanned additional endo-
vascular and surgical procedures performed at the
time of ELG deployment. Thirty day clinical success
was 86.8% ðn ¼ 825Þ:
Length of hospital stay
The mean length of stay (^SD) for patients under-
going endoluminal stent repair is 7.4 (^8.8) days.
Mortality
Peri-operative mortality was 16/950 (1.7%). The main
cause of death was cardiac-related (43%, n ¼ 7),
however, neurological and intra-abdominal compli-
cations accounted for a further 7 deaths.
Ten of the 16 perioperative deaths were amongst
patients who were not considered suitable for open
repair (2.4%, n ¼ 410). Five perioperative deaths
occurred in patients whose aneurysms measured less
than 5.5 cm (1.2%, n ¼ 408).
Procedural complications
Graft related complications included failed access,
access vessel complications, failed and misplaced
deployment of endografts, imperfect seal, twist/
kink/obstruction and embolisation. The overall rate
for these complications was 13.7% ðn ¼ 131Þ; with
Table 1. ASA classification and aneurysm size
Aneurysm size (mm) Number of subjects Percent of aneurysms of that size (%)
ASA I or II ,55 175 44
ASA III ,55 212 54
ASA IV ,55 9 2
ASA I or II #50 108 44
ASA III #50 131 54
ASA IV #50 6 2
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imperfect seal accounting for 5.3% ðn ¼ 51Þ of these
(Fig. 2). Prior to discharge a further 12 cases (1.2%) of
graft migration or thrombosis were noted. For patients
whose aneurysms measured less than 5.5 cm the graft
related complication rate was 10.5% ðn ¼ 43=408Þ:
Seventy complications were noted for patients who
were unsuitable for open repair (17%, n ¼ 410).
Surgeons noted a range of systemic complications
with an overall rate (excluding pyrexia) of 18.6% ðn ¼
177Þ; the leading cause attributed to cardiac-related
complications (7.2%, n ¼ 69). Access site and lower
limb complications were experienced by 7.8% ðn ¼ 74Þ
of patients, with bleeding, haematoma and false
aneurysm being the major grouping (3.8%, n ¼ 36).
Sixty patients with aneurysms less than 5.5 cm
experienced systemic complications (14.7%, n ¼ 408)
and 109 patients unsuitable for open repair had
systemic complications (26.6%, n ¼ 410).
Additional procedures
A number of patients had additional procedures
during the same hospital admission period. At the
time of the procedure, 23.5% ðn ¼ 223Þ of patients had
an additional endovascular procedure, 3.1% ðn ¼ 30Þ
had an additional surgical procedure and 0.9% ðn ¼ 9Þ
were converted to an open procedure. After surgery
but prior to discharge a further 2.1% ðn ¼ 20Þ of
patients required further surgical interventions (10
open, 7 endovascular and 3 ‘other’).
Endoleaks
Predischarge type I endoleaks were reported in 2.6%
ðn ¼ 25Þ of cases and type II endoleaks in 4.6% ðn ¼ 44Þ
of cases. Surgeons reported unsuccessful exclusion in
4.5% (41/919) of procedures, however, this increased
to 6.7% (64/950) when the reported incidence of failed
access, failed deployment and type 1 endoleak (prior
to discharge) were included.
Discussion
Endoluminal graft repair (ELG) has rapidly become a
widely adopted procedure in the armamentarium of
vascular surgeons in Australia. This article aims to
review the indications for the procedure amongst
Australian vascular surgeons and initial outcomes.
The cases submitted constitute 87% of all pro-
cedures performed privately in Australia for the audit
period. Results for this procedure have been re-
appraised every 6-months and there has been little
overall change as more patients have been added to
the database, indicating that the data set is robust and
stable. However, the indicators and outcomes of the
remaining 13% of private cases are unknown.
The results suggest that older and sicker patients
are being treated with endoluminal grafts. Surpris-
ingly, a large number of aneurysms (27%, n ¼ 253=921)
are being treated that are #50 mm diameter and 44%
ðn ¼ 407Þ are less than 55 mm in diameter. Fifty six
percent of both patient size groups (# and ,55 mm)
are ASA III or IV. Conversely, a large number (44%) of
smaller aneurysms (#50 mm) are being treated in
relatively healthy patients (ASA I or II) with ELG,
possibly due to the perceived low risk of the procedure
by many Australian surgeons.
Recently published guidelines for the treatment of
AAAs by a subcommittee of the Joint Council of the
American Association for the Vascular Surgery and
Society for Vascular Surgery recommend an interven-
tion threshold of 55 mm in the ‘average risk’ patient
and possible lower threshold in younger fitter patients
and women.5 The guidelines also recommended
delayed repair until larger aneurysm diameters are
reached for higher risk patients.
Clearly Australian surgeons are taking a rather
aggressive approach to the management of aortic
aneurysms, particularly in the moderate to higher risk
groups. Despite treating an elderly population with a
significant number of comorbidities, reported mor-
tality was low (1.7%) and morbidity rates (systemic,
19%, graft related, 13%) were acceptable. Failure to
exclude the aneurysm due to failed access, failed
deployment or early type I endoleak occurred in 6.7%
of cases.
During the audit period, 58% of patients underwent
spiral CT and angiography prior to ELG repair. A totalFig. 2. Graft related complications.
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of 83% underwent angiography. With current rapid
advances in non-invasive imaging, it is likely that
fewer (if any) patients will require invasive imaging in
the future. In this audit period only 11% of patients
underwent CTA without angiography as their work
up.
The majority of surgeons in Australia perform
,10–15 ELG procedures per year which suggests
that they are using the procedure selectively—
offering it to a sicker and/or older patient popu-
lation or those with a ‘hostile’ abdomen, and
perform open repair on healthier patients. A cohort
of surgeons offers the procedure to all patients with
suitable anatomy.
Table 2 compares Australian data with that
published for EUROSTAR. Eurostar initiated its
data collection in 1996. The Australian data repre-
sents a substantial proportion of Zenith (Cook,
Australia) endografts (83%) and compares with an
incidence of 1% in the early Eurostar collection;
however, this has increased to 33% in the more
recent data.10
In conclusion, our experience suggests that the
operative Australian data is robust, having changed
little as extra patients have been added to the audit. As
the length of study increases, so too will the usefulness
of the data in assessing outcomes. Thus far, Australian
data compares favourably with that published else-
where. The long-term data will help to evaluate the
durability of this generation of endografts. By feeding
results back to surgeons the results may also help to
inform practice regarding suitability of treatment for
specific patients.
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Table 2. Comparisons between the Australian audit data and
EUROSTAR
EUROSTAR6–10 Australian data
Perioperative mortality 1.7–2.6% 1.7%
Conversion to open 1.0–1.7% 1%
Graft migration 0.3–2% 0.5%
Endoleak (discharge) 16% 7%
Systemic complications 12–18% 23%
Cardiac 3–5% 7%
Pulmonary 1.8–3% 5%
Renal 2–3% 3.6%
Cerebral 0.7–1.5% 2.0%
Hepatobiliary 0.1–0.3% 0.3%
Male 91–95% 86%
Age (mean) 71 75.0
Aneurysm size (mean) 57 mm 57 mm
ASA I 7–9% 3%
ASA II 35–39% 31%
ASA III 44–45% 58%
ASA IV 6–7% 6.5%
Study period 1996–2003 1999–2001
Zenith (Cook) endografts 1-33% 83%
EUROSTAR: N ¼ 15546–10–4242.10
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